Alex Rider

Alex Rider

Auto-generated profile, based on publicly available information

Alex Rider

Adelphi Real World, Bollington, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2013 in BMC Urology
Verified
Journal Article
Open access
PDF file
CSCora N. Sternberg
Cora N. Sternberg
EBEdwina S Baskin-Bey
Edwina S Baskin-Bey
MWMark Watson
Mark Watson
AWAndrew Worsfold
Andrew Worsfold
ARAlex Rider
Alex Rider
BTBertrand TOMBAL
Bertrand TOMBAL
European treatment guidelines recommend the use of hormonal therapy for the treatment of advanced prostate cancer, including castration-resistant prostate cancer (CRPC), but there is little understanding of how common practices in prostate cancer treatment compare across Europe. The aim of this analysis was to evaluate the management of CRPC patients across five European countries (France, Germany, Italy, Spain and the UK).

1 February 2019 in Journal of Bone Oncology
Verified
Journal Article
Open access
JBJean-Jacques Body
Jean-Jacques Body
RMRoger von Moos
Roger von Moos
ARAlex Rider
Alex Rider
PHPamela Hallworth
Pamela Hallworth
DBDebajyoti Bhowmik
Debajyoti Bhowmik
YQYi Qian
Yi Qian
Bone metastases (BMs) are common in patients with prostate cancer and can lead to skeletal-related events (SREs), which are associated with increased pain and reduced quality of life (QoL). Bone-targeted agents (BTAs), such as zoledronic acid and denosumab, reduce the incidence of SREs and delay progression of bone pain. We evaluated the management of BMs and pain in six European countries (Belgium, France, Germany, Italy, Spain and the UK) using the Adelphi Prostate Cancer Disease Specific Programme. Patient-reported outcomes (PROs) were used to assess the impact of BMs on pain and QoL. In total, 358 physicians completed Patient Record Forms, of whom 246 were oncologists and 112 were urologists. Data were collected on 3667 patients with prostate cancer, including 1971 with BMs and 551 with metastases at sites other than bone (non-BMs). PROs were assessed in 573 patients with BMs and 220 with non-BMs. Most patients with BMs (74%) received a BTA and 53% received treatment within 3 months of BM diagnosis. Patients treated by oncologists were more likely than those treated by urologists to receive a BTA (78% vs. 60%) and to have treatment initiated within 3 months of BM diagnosis (56% vs. 43%). For patients who did not receive a BTA, the main reasons for not treating were very recent BM diagnosis and a perceived low risk of bone complications. Data collected by physicians showed that most patients with BMs (97%) were taking analgesics, with 30% receiving strong opioids. Despite this, 70% were currently experiencing bone pain and 28% were experiencing moderate to severe pain. PRO pain measures showed that 70% of patients with BMs were experiencing moderate to extreme pain, suggesting a disparity between pain levels reported by physicians and by patients. Although most patients with BMs receive a BTA, there remain a proportion of patients who are not receiving adequate treatment to prevent SREs or manage pain. Oncologists are more likely to adhere to clinical guidelines than urologists for the prescription of BTAs. Bone pain is common and undertreated. Increasing awareness of SRE prevention and bone pain management might improve patient care.

14 January 2022 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
PGPip Griffiths
Pip Griffiths
JPJohn Devin Peipert
John Devin Peipert
ALAndrea Leith
Andrea Leith
ARAlex Rider
Alex Rider
LMLucy Morgan
Lucy Morgan
KCKim Cocks
Kim Cocks
Purpose: With higher efficacy of cancer therapies, the numbers and types of side effects experienced by patients have also increased, evidencing a need for brief assessments of side effect bother. The Functional Assessment of Cancer Therapy-General (FACT-G) includes the item “I am bothered by side effects of treatment” (GP5). This study aimed to confirm GP5’s validity in a large, diverse, real-world patient sample. Methods: Real-world data were drawn from 10 Adelphi Disease Specific Programmes (DSP™) conducted between 2015 and 2019 in France, Germany, Italy, Spain, the UK and the USA, covering 10 cancer sites. We examined correlations between GP5 responses and varied measures of patient-reported global health and the number of side effects experienced. We explored whether more advanced patients and those with worse Eastern Cooperative Oncology Group Performance Status Rating (ECOG PSR) reported greater side effect bother. Finally, we conducted differential item functioning (DIF) assessment using the Mantel–Haenszel approach. Results: The sample included 6755 advanced cancer patients. GP5 responses were distributed similarly across most cancer sites. A moderate, negative correlation (rpolyserial = − 0.43) between GP5 responses and global health evidenced convergent validity. Known groups validity was evidenced by dichotomised distributions of GP5, showing expected results between cancer stage 2 vs. 3 and 4 and with ECOG PSR (p < 0.001). Little evidence of DIF was found. Conclusion: GP5 exhibited evidence of validity across cancer sites and countries and appeared to measure the same construct across these countries. GP5 has significant promise as a summary indicator of side effect bother.

26 March 2019 in Future Oncology
Verified
Journal Article
Closed access
CMCarla M Mamolo
Carla M Mamolo
JCJoseph C Cappelleri
Joseph C Cappelleri
CHCaroline J Hoang
Caroline J Hoang
RKRuth Kim
Ruth Kim
AHAnna Hadfield
Anna Hadfield
RWRoland B Walter
Roland B Walter
Aim: We used Adelphi Real World Disease-Specific Programme data to characterize adults with newly diagnosed or relapsed/refractory de novo acute myeloid leukemia (AML). Materials & methods: Community-practice hematologists/oncologists completed patient record forms for their regular AML patients. Patients were invited to complete patient self-completion forms including 3-Level EuroQol 5-Dimensions (EQ-5D-3L) and Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu) questionnaires. Results: Physicians provided patient record forms for 389 patients (339 newly diagnosed, 50 relapsed/refractory); 68 patients completed patient self-completion forms. Mean EQ-5D visual–analog scale and index and FACT-General scores were significantly lower than US population norms (p < 0.0001); health-related quality of life (HRQoL) scores were generally lower than 11 other cancers. Conclusion: HRQoL impairment is grave in AML. Efforts are needed to improve HRQoL in affected patients.

31 January 2022 in Future Oncology
Verified
Journal Article
Open access
MLMichael Patrick Lux
Michael Patrick Lux
KLKatie Lewis
Katie Lewis
ARAlex Rider
Alex Rider
ANAlexander Niyazov
Alexander Niyazov
Aim: We assessed real-world patient demographics and BRCA1/2 mutation testing rates among adult women with HER2-negative advanced breast cancer (ABC). Methods: Oncologists across the USA and in Fra... Plain language summary This study investigated the use of BRCA1/2 genetic testing in women with breast cancer in the USA and Europe. This is important, as mutations in this gene are known to influe...

18 June 2021 in Pain Management
Verified
Journal Article
Open access
BQBarry Quinn
Barry Quinn
HLHeinz Ludwig
Heinz Ludwig
ABAbigail Bailey
Abigail Bailey
KKKeerun Khela
Keerun Khela
AMAndrea Marongiu
Andrea Marongiu
ASAnouchka Seesaghur
Anouchka Seesaghur
Aim: To describe physical, social and emotional aspects of pain self-reported by patients with multiple myeloma (MM), and patient–physician communication of physical pain. Materials & methods: We a...